| Literature DB >> 33384596 |
K Reeta Vijayarani1, Manoj Govindarajulu2, Sindhu Ramesh2, Mansour Alturki2,3, Mohammed Majrashi4, Ayaka Fujihashi2, Mohammed Almaghrabi2,5, N Kirubakaran1, Jun Ren6, R Jayachandra Babu2, Forrest Smith2, Timothy Moore2, Muralikrishnan Dhanasekaran2.
Abstract
Chronic inflammation is a key culprit factor in the onset and progression of several diseases. Novel and pharmacologically effective therapeutic approaches are needed for new treatment remedy or improved pharmacokinetics and pharmacodynamics for existing synthetic drugs, in particular natural products. Boswellic acids are well-known natural products, with capacity to effectively retard inflammation without severe adverse effects. However, the therapeutic use of Boswellic acids are greatly hindered by its poor pharmacokinetic properties. Co-administration strategies that facilitate the oral absorption and distribution of Boswellic acids should lead to a safe and more effective use of this product prophylactically and therapeutically in inflammatory disorders. In this study, we examined the effect of Piper longum extract on the absorption and bioavailability of Boswellic acid in rabbits. In addition, we further explored computational pharmacodynamic interactions between Piper longum and Boswellic acid. Piper longum extract at 2.5 and 10 mg/kg, increased the bioavailability of Boswellic acid (p < 0.05). Based on our drug-based computational modeling, cytochrome P450 (CYP450)-mediated mechanism was involved in increased bioavailability. These findings confirmed that Piper longum with Boswellic acid may be administered orally together for effective therapeutic efficacy. Thus, our studies support the application of Piper longum with Boswellic acid as a novel therapeutic avenue in diseases associated with inflammation.Entities:
Keywords: Piper longum extract; anti-inflammatory; bioavailability; boswellic acid; computational analysis; natural products
Year: 2020 PMID: 33384596 PMCID: PMC7770183 DOI: 10.3389/fphar.2020.551911
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810